Shilpa Medicare Leads Global Innovation with First-Ever NorUDCA Approval

Shilpa Medicare Limited has secured the world's first regulatory approval for NorUDCA, a groundbreaking therapy for NAFLD, from India's CDSCO. As an innovative leader in hepatology, the company aims to rapidly launch the drug in India and pursue international approvals, expanding access to life-changing treatments worldwide.